MANAGEMENT TEAM

Lycera’s senior management team is comprised of leaders with deep experience spanning the entire value chain, from drug discovery and development through commercialization. Lycera’s scientists are thought leaders in immunology, inflammation, organ transplantation and kinase biology, who collectively represent 125 years of experience, and have been responsible for key advances and discoveries in their respective fields.

William J. Sibold

President and Chief Executive Officer

Bill Sibold is an accomplished leader with more than 20 years of pharmaceutical and biotechnology experience, with a focus on commercial operations, business development, general management and strategic planning. Prior to joining Lycera as CEO in 2010, Mr. Sibold was senior vice president, U.S. commercial at Biogen Idec, where he led the over $2.5 billion U.S. business that consisted of the oncology, rheumatology and neurology therapeutic areas. During his eight-year tenure at Biogen Idec, Mr. Sibold held multiple senior leadership roles at the company, which included growing the U.S. commercial business (Rituxan®, Avonex®, Tysabri®), leading the company’s new products group and managing the Australia and Asia Pacific regions. Mr. Sibold began his career in the biopharmaceutical industry with Eli Lilly Canada in sales and marketing, and then at Amgen in Epogen’s strategic marketing group.

In addition to his biotech and pharmaceutical experience, Mr. Sibold led the business development and sales departments of ICSL, one of the first site management organizations in the country that operated over 50 clinical trial sites with Phase 1 through 4 trial capabilities.

Mr. Sibold holds an M.B.A. from Harvard University and a B.A. in molecular biophysics and biochemistry from Yale University.

Paul S. Changelian, Ph.D.

Vice President of Biology

Dr. Paul S. Changelian is a key member of Lycera’s drug discovery and development team and an expert in autoimmune diseases, organ transplantation and kinase biology. Prior to joining Lycera in 2009, Dr. Changelian worked nearly 20 years as a researcher for Pfizer in several roles, including director of inflammation biology. His lab’s chief concern was the identification of molecular targets that would lead to drugs preventing renal transplant rejection. His work culminated in 2000 with the discovery of CP-690,550, a compound that has since shown efficacy in Phase 2 trials for renal transplantation and is currently in Phase 3 trials for rheumatoid arthritis and Phase 2 trials for multiple sclerosis, inflammatory bowel disease, psoriasis and dry eye. Most recently, Dr. Changelian led his own pharmaceutical consulting company.

Dr. Changelian’s work has been published in nearly 30 peer-reviewed publications, including Science. In addition to his role at Lycera, Dr. Changelian is an adjunct assistant professor of internal medicine at the University of Michigan Medical School.

Dr. Changelian received a Ph.D. in immunology from Harvard University and completed his postdoctoral studies at Washington University at St. Louis.

Gary D. Glick, Ph.D.

Founder and Chief Scientific Officer

Dr. Gary D. Glick founded Lycera in 2006, and was responsible for raising the seed round and Series A financing for the company. Since 1990, Dr. Glick has been a member of the chemistry faculty at the University of Michigan in Ann Arbor, where he presently holds the Werner E. Bachmann Chair in Chemistry. In addition, he is a professor in the department of biological chemistry at the University of Michigan Medical School and is a member of the training faculty for the interdepartmental immunology and medicinal chemistry doctoral programs. He is also the founder and director of the chemical biology doctoral program at Michigan. Dr. Glick’s research interests focus on drug discovery and development for autoimmune diseases and cancer, chemical-induced apoptosis, nucleic acid structure, folding and recognition, and molecular recognition of nucleic acids by proteins.

Dr. Glick has served and continues to serve on numerous boards and committees, including the Bioorganic & Natural Products Chemistry Study Section of the National Institutes of Health and the scientific advisory board of the National Arthritis Foundation, Michigan Chapter. He serves on several editorial boards, is editor-in-chief of Biopolymers, a leading journal publishing in the areas of biochemistry and biophysics, and is a counselor to the American Chemical Society Division of Biological Chemistry.

Dr. Glick’s scientific contributions have been recognized with a number of different awards including an Arthritis Investigator Award from the National Arthritis Foundation, a Junior Faculty Research Award from the American Cancer Society, a Young Investigator Award from the National Science Foundation, a Camille Dreyfus Teacher-Scholar Award, a Research Fellowship from the Alfred P. Sloan Foundation and two Research Excellence Awards from the University of Michigan. He is also a fellow of the American Association for the Advancement of Science.

Dr. Glick received a Ph.D. from Columbia University and completed a National Institutes of Health postdoctoral fellowship at Harvard University.

Robin S. Goldstein, Ph.D.

Vice President of Preclinical Development and Program Management

Dr. Robin S. Goldstein brings to Lycera 25 years of drug development experience across pharmaceutical and biotechnology R&D organizations. Prior to joining Lycera in 2010, Dr. Goldstein was vice president, preclinical development and project management at ArQule. Prior to ArQule, Dr. Goldstein spent 14 years at Novartis, where she held positions of increasing responsibility in global project management as international project leader across a wide variety of therapeutic areas spanning the entire R&D life cycle, which was preceded by her leadership role in preclinical development.

A recognized expert in toxicology, Dr. Goldstein has been an editor on five books and 15 book chapters, and was previously a full member of the National Institutes of Health Toxicology Study Section and an elected officer in the Society of Toxicology.

Dr. Goldstein received a Ph.D. from Michigan State University.

Peter L. Toogood, Ph.D.

Vice President of Chemistry and Chemical Biology

Dr. Peter L. Toogood is an expert in immunology, inflammation, infectious diseases and cancer, helping to lead Lycera’s efforts to develop novel small-molecule pharmaceuticals to treat autoimmune diseases. Dr. Toogood joined Lycera in 2009, after working as a research scientist and manager at Parke-Davis and Pfizer. He has led teams in cancer and infectious disease drug discovery and was an inventor of the first selective cyclin-dependent kinase 4 inhibitor to enter human clinical trials. Prior to that, he was a faculty member in the department of chemistry at the University of Michigan. There, he established a research program in natural products total synthesis and chemical biology, funded by the National Institutes of Health and the National Science Foundation.

Dr. Toogood is the author of more than 40 peer-reviewed publications, several patents and multiple pending patent applications. In addition to his work at Lycera, Dr. Toogood is an adjunct professor in the University of Michigan College of Pharmacy.

Dr. Toogood received a Ph.D. from Imperial College in London and was a NATO postdoctoral fellow at Harvard University.